GLP-1 Evidence

Próifíl druga

Semaglutide: cad a léiríonn na trialacha

Agonist glp-1. Instealladh seachtainiúil; tá foirm ó bhéal laethúil ann freisin.

Updated 3 min read 14 citations

Pinn inslin daonna de 100 aonad in aghaidh an mhilli-léitheora leagtha ar chúlra buí
Wesalius · CC BY 4.0 · Wikimedia Commons

Cad a thacaíonn an cruthúnas

Tuairiscigh STEP 1 laghdú meán meáchain comhlán de thart ar 15% ag 68 seachtain i gcomparáid le thart ar 2.4% ar phlaicéad. Tuairiscigh SELECT ina dhiaidh sin laghdú ar imeachtaí cardiovascular tromchúiseacha i daoine le meáchan iomarcach agus galar cardiovascular bunaithe ach gan diaibéiteas. [1]

Tá éifeachtaí gastrointestinal coitianta agus is é sin an chúis ghnáth a stopann daoine. Tá athbhuaileadh meáchain tar éis stopadh suntasach agus tá sé go maith doiciméadaithe — léirigh STEP 4 go raibh an chuid is mó den chaillteanas ag teacht ar ais laistigh de bhliain tar éis cóireála.

Láithreacht fianaise trasna na ndrugaí inkretin atá curtha in iúl De na 6 drugaí inkretin agus ullmhóidí atá curtha in iúl, léiríonn sé cé mhéad atá ag gach leibhéal fianaise, le Semaglutide grádaithe mar bhunaithe. Established4 drugsPromising1 drugsPopular but weak1 drugs
Tá Semaglutide grádaithe mar bhunaithe. Déanann an grád cur síos ar cháilíocht na fianaise trialach, ní ar conas a oireann an druga do dhuine ar bith — agus tá an t-aon iontráil a grádíodh "coitianta ach laige" ann go díreach toisc go bhfuil sé á dhíol go forleathan agus nár cuireadh trialacha air. Gráid a shocraítear ó chlár triala agus stádas rialála.

Cad a tharlaíonn nuair a stopann tú

Is é seo an chuid den phictiúr a fhágann go minic. Taispeánann trialacha tarraingthe go comhoibrithe go leanúnach go dtéann meáchan ar ais go suntasach laistigh de bhliain tar éis stopadh, agus go dtéann marcóirí cardio-metabolacha ar ais leis [2]. Ní teip é sin ar an druga — is é sin conas a looks cóireáil a dhéanamh ar choinníoll crónach le druga nuair a bhíonn an druga bainte amach.

Is é an t-implíocht phraicticiúil ná go bhfuil an cinneadh chun tosú ina chinneadh faoi fhadtéarma, lena n-áirítear costais agus rochtain thar an bhfadtéarma sin, seachas faoi mheáchan sprioc.

Mais muscle

Téann meáchan tapa ó aon chúis i gcuimhne le tissú leanaí, agus ní bhíonn trialacha inkretin ina eisceacht. Tá an cóimheas a chailltear mar mhás leanaí cosúil go forleathan le modhanna caillteanais tapa eile, ach tá an caillteanas iomlán níos mó toisc go bhfuil an caillteanas iomlán níos mó. Is iad próitéin chuí agus traenáil frithsheasmhach na hidirghníomhaíochtaí atá le fianaise ina dhiaidh sin, agus tá an dá cheann laistigh d'údarás do do leigheas.

Árasán cógaisíochta ar an talamh ar Teltower Damm i Berlin-Zehlendorf, an Ghearmáin
Singlespeedfahrer · CC0 · Wikimedia Commons

Drugaí eile sa rang seo

Cé mhéad meáchain a chailltear ar semaglutide?
Tuairiscigh STEP 1 laghdú meán meáchain comhlán de thart ar 15% ag 68 seachtain i gcomparáid le thart ar 2.4% ar phlaicéad. Tuairiscigh SELECT ina dhiaidh sin laghdú ar imeachtaí cardiovascular tromchúiseacha i daoine le meáchan iomarcach agus galar cardiovascular bunaithe ach gan diaibéiteas. Is iad sin na meáin trialach; athraíonn freagairt aonair go forleathan agus faigheann rannpháirtithe trialach tacaíocht atá mar chuid den toradh.
Cad a tharlaíonn má stopaim?
Téann an chuid is mó den mheáchan ar ais, go ginearálta laistigh de bhliain. Tá trialacha tarraingthe comhoibrithe comhoibrithe ar seo agus is é an rud is tábhachtaí a thuiscint sula dtosaíonn tú.
An gcuireann sé le caillteanas muscle?
Téann meáchan tapa ó aon chúis i gcuimhne le tissú leanaí. Is iad iontógáil próitéine agus traenáil frithsheasmhach na hidirghníomhaíochtaí atá le fianaise ina dhiaidh sin.
An bhfuil leagan comhoibrithe mar an rud céanna?
Níl. Ní hionann ullmhúcháin comhoibrithe agus na táirgí a cuireadh triail orthu, tá earráidí dáileachta leagtha síos, agus tá roinnt ag úsáid foirmi salt nach raibh staidéar déanta orthu riamh i ndaoine.

References

Every citation below links to the original peer-reviewed record on PubMed or via DOI. Nothing here is a substitute for medical advice.

  1. Efficacy of tirzepatide, lanifibranor, and resmetirom in metabolic dysfunction-associated steatotic liver disease: a meta-analysis of high-quality randomized controlled trials Zhao S, Tian F, Yu L, et al. · Internal and emergency medicine · 2026 · Meta-analysis DOIPubMed 41917519
  2. Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials Ciudin A, Sapin H, Fan L, et al. · Advances in therapy · 2026 · Meta-analysis DOIPubMed 41820778Full text
  3. Effectiveness & safety of semaglutide in weight reduction in obese nondiabetic patients: A systematic review and meta-analysis Naz F, Qaiser F, Mumtaz A, et al. · Medicine · 2026 · Meta-analysis DOIPubMed 42536519Full text
  4. Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement Oprea AD, Ostapenko LJ, Sweitzer B, et al. · British journal of anaesthesia · 2025 · Systematic review DOIPubMed 40379536Full text
  5. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis Karakasis P, Patoulias D, Fragakis N, et al. · Metabolism: clinical and experimental · 2025 · Meta-analysis DOIPubMed 39719170
  6. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials Badve SV, Bilal A, Lee MMY, et al. · The lancet. Diabetes & endocrinology · 2025 · Meta-analysis DOIPubMed 39608381
  7. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials Moiz A, Filion KB, Toutounchi H, et al. · Annals of internal medicine · 2025 · Systematic review DOIPubMed 39761578
  8. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials Karagiannis T, Malandris K, Avgerinos I, et al. · Diabetologia · 2024 · Meta-analysis DOIPubMed 38613667Full text
  9. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary Diabetologia · 2024 · Clinical guideline DOIPubMed 38869512Full text
  10. Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Moiz A, Levett JY, Filion KB, et al. · The American journal of cardiology · 2024 · Meta-analysis DOIPubMed 38679221
  11. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) Journal of hepatology · 2024 · Clinical guideline DOIPubMed 38851997
  12. A systematic review of the effect of semaglutide on lean mass: insights from clinical trials Bikou A, Dermiki-Gkana F, Penteris M, et al. · Expert opinion on pharmacotherapy · 2024 · Systematic review DOIPubMed 38629387
  13. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis Yao H, Zhang A, Li D, et al. · BMJ (Clinical research ed.) · 2024 · Meta-analysis DOIPubMed 38286487Full text
  14. Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis Stefanou MI, Theodorou A, Malhotra K, et al. · European stroke journal · 2024 · Meta-analysis DOIPubMed 38400569Full text

This page was translated automatically from English. The citations and numbers are unchanged. Read the English original if anything reads oddly. Read the English original